Cerebrolysin

Overview

Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.

Mechanism of Action

The proposed mechanism is neurotrophic-like activity, with preclinical data suggesting effects mimicking CNTF, BDNF, and NGF and promoting neurogenesis, synaptogenesis, and neuronal survival via PI3K/Akt and MAPK/ERK signaling. Because Cerebrolysin is a heterogeneous porcine-brain hydrolysate rather than a defined molecule, the precise mechanism and the identity of the active constituents remain poorly characterized.

Research Summary

Clinical evidence is real but methodologically uneven. The CASTA trial (Heiss 2012, n=1070) missed its primary endpoint in Asian ischemic stroke patients but showed favorable trends in the severe-stroke subgroup. The CARS trial (Muresanu 2016) reported improved upper-extremity motor recovery at day 90. Vascular-dementia RCTs (e.g., Guekht 2011) showed improvements on ADAS-cog+ and CIBIC+. A 2023 Cochrane review concluded moderate-certainty evidence shows no benefit on all-cause death in acute ischemic stroke and noted a possible increase in non-fatal serious adverse events. Many pivotal trials are industry-sponsored.

Dosing Information

Reported Side Effects

• Injection site reactions
• Dizziness
• Headache
• Sweating
• Nausea
• Agitation or insomnia
• Rare hypersensitivity/anaphylaxis (biologic porcine-derived product)

Research References

• Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke 2012;43(3):630-636 (2012)
• Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke 2016;47(1):151-159 (2016)
• Guekht AB et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2011;20(4):310-318 (2011)
• Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 2023;10:CD007026 (2023)